SMAD2 and lung carcinoma: The introduction of silencing SMAD2 reversed the effect of miR-125a-3p inhibitor on the biological activity of lung cancer cells, suggesting that LINC01132 may participate in the progression of lung cancer by mediating the miR-125a-3p/SMAD2 axis.